Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Operating Income (2020 - 2025)

Foghorn Therapeutics has reported Operating Income over the past 6 years, most recently at -$23.9 million for Q4 2025.

  • Quarterly results put Operating Income at -$23.9 million for Q4 2025, up 0.53% from a year ago — trailing twelve months through Dec 2025 was -$86.4 million (up 15.87% YoY), and the annual figure for FY2025 was -$86.4 million, up 15.87%.
  • Operating Income for Q4 2025 was -$23.9 million at Foghorn Therapeutics, down from -$18.5 million in the prior quarter.
  • Over the last five years, Operating Income for FHTX hit a ceiling of -$17.1 million in Q3 2023 and a floor of -$33.3 million in Q1 2023.
  • Median Operating Income over the past 5 years was -$25.9 million (2021), compared with a mean of -$25.7 million.
  • Biggest five-year swings in Operating Income: crashed 68.54% in 2021 and later skyrocketed 39.56% in 2023.
  • Foghorn Therapeutics' Operating Income stood at -$28.1 million in 2021, then dropped by 13.55% to -$31.9 million in 2022, then grew by 20.16% to -$25.5 million in 2023, then grew by 5.71% to -$24.0 million in 2024, then increased by 0.53% to -$23.9 million in 2025.
  • The last three reported values for Operating Income were -$23.9 million (Q4 2025), -$18.5 million (Q3 2025), and -$21.1 million (Q2 2025) per Business Quant data.